Announcement on Voluntary Disclosure of Interim Analysis Results Obtained from Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)

About this update from Hinova Pharmaceuticals, Inc. Class A

Announcement on Voluntary Disclosure of Interim Analysis Results Obtained from Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH) The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Hinova Pharmaceuticals, Inc. Class A